SUCCESSFUL USE OF AN INTERLEUKIN 17 INHIBITOR (SECUKINUMAB) IN THE TREATMENT OF ISOLATED DESTRUCTIVE ENTHESITIS IN PSORIATIC ARTHRITIS
Enthesitis is inflammation at the site of attachment of tendon, ligament, or joint capsule to bone, a typical symptom of psoriatic arthritis (PsA). Heel enthesitis is of the greatest clinical significance. The activation of the interleukin 23/interleukin 17 (IL-23/IL-17) axis plays a pivotal role in...
Main Authors: | E. E. Gubar, E. Yu. Loginova, T. V. Korotaeva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2018-11-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2633 |
Similar Items
-
Experience in using secukinumab in patients with axial psoriatic arthritis
by: E. E. Gubar, et al.
Published: (2020-11-01) -
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
by: Laura C. Coates, et al.
Published: (2019-12-01) -
Enthesitis in psoriatic arthritis
by: Mihaela Agache, et al.
Published: (2021-09-01) -
ENTHESITIS AND PSORIATIC ONYCHOPATHY AS A FACTOR FOR PREDICTION OF PSORIATIC ARTHRITIS IN PSORIASIS
by: Tatyana G. Sidorcika, et al.
Published: (2018-04-01) -
The safety and optimal dosage of an interleukin-17A inhibitor (secukinumab) in the treatment of psoriatic arthritis in a patient with concomitant hepatitis C virus infection
by: E. E. Gubar, et al.
Published: (2019-10-01)